Attention Deficit Hyperactivity Disorder Market Size, Share & Trends Analysis Report By Drug Type (Stimulants, Non-stimulants), By Demographics (Children, Adults), By Distribution Channel, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global attention deficit hyperactivity disorder market size was exhibited at USD 13.23 billion in 2022 and is projected to hit around USD 20.55 billion by 2032, growing at a CAGR of 4.5% during the forecast period 2023 to 2032.

Key Pointers:

• The stimulant drug type segment dominated the attention deficit hyperactivity disorder market with a revenue share of 71.97% in 2022
• The adults segment dominated the attention deficit hyperactivity disorder (ADHD) market with a revenue share of 58.85% in 2022.
• The retail pharmacy segment dominated the attention deficit hyperactivity disorder market with a revenue share of 73.78% in 2022 
• North America dominated the attention deficit hyperactivity disorder market in terms of the revenue share of 74.59% in 2022.
• Asia Pacific is expected to witness a growth rate of 6.4% over the forecast period.

 Attention Deficit Hyperactivity Disorder Market Report Scope

The presence of a strong product pipeline for the treatment of ADHD and their subsequent approval is expected to boost the market growth. Some late-stage pipeline products are NRCT-101 developed by Neurocentria, Inc., SPN-812 by Supernus Pharmaceuticals, Inc., and EB-1020 by Otsuka America Pharmaceutical, Inc.

Several initiatives undertaken by government bodies regarding early diagnosis and treatment of ADHD are likely to support the market growth. In January 2021, the Australian Government included Vyvanse under its Pharmaceutical Benefits Scheme (PBS) for the treatment of adult patients with ADHD. This inclusion makes the availability of Vyvanse at a subsidized rate to patients and more than 20,000 patients received a comparable treatment for the disease at low cost and benefits. Without PBS subsidy, the patients had to pay more than USD 1,200 per person annually for their treatment. After the inclusion in PBS, they will receive the treatment at USD 41.30 per script. Such initiatives are also expected to drive market growth.

Increasing awareness about ADHD among patients, physicians, and other healthcare providers may increase the demand for diagnosis and treatment which in turn propel the growth of the attention deficit hyperactivity disorder market. The Attention Deficit Hyperactivity Disorder Coaches Organization (ACO) celebrates October as the ADHD awareness month intending to raise awareness, generate funding for R&D, and educate people about disorders. This initiative may boost early diagnosis, thereby, increasing product penetration.

However, the risk of comorbidity with other psychiatric disorders is high among children with ADHD, often making diagnosis and treatment of the disorder complex. A research study published by the Lundbeck Foundation in 2021 showed that ADHD patients with other psychiatric comorbid conditions were more likely to avoid taking medicines. Some of the comorbid conditions that typically occur in ADHD pediatric patients are depression, anxiety, bipolar disorder, learning disorder, early speech/communication problems, and oppositional defiant disorder.

Furthermore, the shortage of stimulants to treat ADHD has forced patients to pay for expensive branded medication and create scope for substitute therapies, such as behavioral therapy, which will negatively impact the demand for ADHD pharmacological therapies. Strict regulations are implemented by regulatory bodies, such as the U.S. Drug Enforcement Administration (DEA), which limit the production of ADHD drugs to avoid misuse or abuse. Amid an increase in demand, this can create a shortage of medical products, consequently increasing the cost of treatments and restraining market growth. Thus, the shortage of medicines may impede the market growth.

Some of the prominent players in the Attention Deficit Hyperactivity Disorder Market include:

• Eli Lilly and Company.
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Lupin
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Mallinckrodt Inc.
• Purdue Pharma LP
• NEOS Therapeutics Inc.
• Supernus Pharmaceutical, Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Attention Deficit Hyperactivity Disorder market.

By Drug Type 

• Stimulants
  • Amphetamine
  • Methylphenidate
  • Lisdexamfetamine
  • Dexmethylphenidate
• Non-stimulants
  • Atomoxetine
  • Guanfacine
  • Clonidine
  • Others

By Demographics 

• Children (2 to 17 years of age)
• Adults

By Distribution Channel 

• Retail Pharmacy
• Hospital Pharmacy

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)